ID   SV-HUC-1
AC   CVCL_3798
SY   HUC-1; SV-HUC; SVHUC
DR   BTO; BTO:0003908
DR   CLO; CLO_0009177
DR   ATCC; CRL-9520
DR   BCRC; 60358
DR   BioSample; SAMN03471218
DR   CCRID; 3101HUMTCHu169
DR   CLS; 305075
DR   Cosmic; 687554
DR   KCB; KCB 2012112YJ
DR   Wikidata; Q54970934
RX   Patent=US4980290;
RX   PubMed=1311637;
RX   PubMed=1767334;
RX   PubMed=2822239;
RX   PubMed=2835156;
RX   PubMed=2841047;
RX   PubMed=15846775;
RX   PubMed=27270441;
WW   https://www.synapse.org/UC25
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9520.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Ureter; UBERON=UBERON_0000056.
CC   Cell type: Epithelial cell; CL=CL_0000066.
ST   Source(s): ATCC=CRL-9520; PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12,13
ST   D16S539: 11
ST   D18S51: 15,16
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 14,17
ST   D5S818: 12,14
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 21,22
ST   Penta D: 13
ST   Penta E: 10,20
ST   TH01: 9,9.3
ST   TPOX: 8,10
ST   vWA: 14
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   11Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   Patent=US4980290;
RA   Reznikoff C.A., Christian B.J.;
RT   "Human uroepithelial cell.";
RL   Patent number US4980290, 25-Dec-1990.
//
RX   PubMed=1311637;
RA   Klingelhutz A.J., Wu S.-Q., Huang J., Reznikoff C.A.;
RT   "Loss of 3p13->p21.2 in tumorigenic reversion of a hybrid between
RT   isogeneic nontumorigenic and tumorigenic human uroepithelial cells.";
RL   Cancer Res. 52:1631-1634(1992).
//
RX   PubMed=1767334; DOI=10.1007/BF01233620;
RA   Klingelhutz A.J., Wu S.-Q., Reznikoff C.A.;
RT   "Nonrandom chromosome losses in tumorigenic revertants of hybrids
RT   between isogeneic immortal and neoplastic human uroepithelial
RT   cells.";
RL   Somat. Cell Mol. Genet. 17:551-565(1991).
//
RX   PubMed=2822239;
RA   Christian B.J., Loretz L.J., Oberley T.D., Reznikoff C.A.;
RT   "Characterization of human uroepithelial cells immortalized in vitro
RT   by simian virus 40.";
RL   Cancer Res. 47:6066-6073(1987).
//
RX   PubMed=2835156;
RA   Meisner L.F., Wu S.-Q., Christian B.J., Reznikoff C.A.;
RT   "Cytogenetic instability with balanced chromosome changes in an SV40
RT   transformed human uroepithelial cell line.";
RL   Cancer Res. 48:3215-3220(1988).
//
RX   PubMed=2841047; DOI=10.1093/carcin/9.8.1427;
RA   Reznikoff C.A., Loretz L.J., Christian B.J., Wu S.-Q., Meisner L.F.;
RT   "Neoplastic transformation of SV40-immortalized human urinary tract
RT   epithelial cells by in vitro exposure to 3-methylcholanthrene.";
RL   Carcinogenesis 9:1427-1436(1988).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//